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Purpose: Bone defects and nonunions are major clinical skeletal problems. Growth factors are 
commonly used to promote bone regeneration; however, the clinical impact is limited because 
the factors do not last long at a given site. The introduction of tissue engineering aimed to deter 
the diffusion of these factors is a promising therapeutic strategy. The purpose of the present 
study was to evaluate the in vivo osteogenic capability of an engineered bone morphogenetic 
protein-4 (BMP4) fusion protein.
Methods: BMP4 was fused with a nanosized carrier, collagen-binding domain (CBD), derived 
from fibronectin. The stability of the CBD-BMP4 fusion protein was examined in vitro and 
in vivo. Osteogenic effects of CBD-BMP4 were evaluated by computer tomography after 
intramedullary injection without a collagen–sponge scaffold. Recombinant BMP-4, CBD, 
or vehicle were used as controls. Expressions of bone-related genes and growth factors were 
compared among the groups. Osteogenesis induced by CBD-BMP4, BMP4, and CBD was also 
assessed in a bone-defect model.
Results: In vitro, CBD-BMP4 was retained in a collagen gel for at least 7 days while BMP4 
alone was released within 3 hours. In vivo, CBD-BMP4 remained at the given site for at least 
2 weeks, both with or without a collagen–sponge scaffold, while BMP4 disappeared from 
the site within 3 days after injection. CBD-BMP4 induced better bone formation than BMP4 
did alone, CBD alone, and vehicle after the intramedullary injection into the mouse femur. 
 Bone-related genes and growth factors were expressed at higher levels in CBD-BMP4-treated 
mice than in all other groups, including BMP4-treated mice. Finally, CBD-BMP4 potentiated 
more bone formation than did controls, including BMP4 alone, when applied to cranial bone 
defects without a collagen scaffold.
Conclusion: Altogether, nanocarrier-CBD enhanced the retention of BMP4 in the bone, thereby 
promoting augmented osteogenic responses in the absence of a scaffold. These results suggest 
that CBD-BMP4 may be clinically useful in facilitating bone formation.
Keywords: BMP4, bone repair, bone tissue engineering, osteogenesis
Introduction
Bone defects and nonunions remain considerable problems caused by tumor and 
trauma, and their treatment constitutes a major challenge in orthopedic reconstitution 
surgery.1 Autologous bone graft is a standard technique for inducing bone repair; 
 however, clinical benefits are not ensured, and collateral symptoms, including persistent 
site pain, nerve injury, hematoma, infection, and fracture, frequently occur.2 Recent 
advances in the treatment methods include the use of sophisticated biocompatible 
scaffolds, multipotential cell populations and appropriate cellular stimulation at the 
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affected sites. Currently, growth factor-based bone tissue 
engineering has attracted increasing attention.
Many growth factors induce osteogenesis.3 Bone morpho-
genetic proteins (BMPs) are members of the transforming 
growth factor-β (TGFβ) protein superfamily, and are known 
to play pivotal roles in the regulation of bone induction, main-
tenance, and repair.4,5 The US Food and Drug Administration 
has approved two BMPs – BMP2, and BMP7/OP1 – which 
have accompanied orthopedic surgery and are applied with 
an absorbable collagen sponge. The clinical benefits of BMP2 
and BMP7 have been reported;6,7 however, several reports 
described the heterotopic ossification associated with the 
use of BMP2 and BMP7.8–10 To prevent heterotopic bone 
formation and induce successful site specific bone growth 
requires an approach that limits the diffusion of factors to 
target tissues.
BMP4 induces osteogenic differentiation of osteoblasts 
and osteoprogenitors and promotes bone formation,11 thus 
playing a crucial role in the onset of bone and cartilage 
 development and fracture repair.12 In vivo BMP4 gene 
therapy accelerated the repair of bone fractures,13 and per-
formed as well or better when compared with BMP2.14 Thus, 
BMP4 appears to be a viable other approach for treatment of 
bone defects and nonunions. BMP4 alone can be delivered 
by direct injection into the site of concern, but immobilized 
BMP4 can be localized and retained in the targeted site for 
longer periods and thus extend the functional half-life of this 
factor. Very recently, we have created a novel collagen-poly 
lactic-co-glycolic acid hybrid scaffold with a BMP4 fused to 
an additional collagen-binding domain (CBD) derived from 
fibronectin (CBD-BMP4).15 CBD-BMP4 exhibited stronger 
and more stable collagen-binding activity than did wild type 
BMP4. This fusion protein, bound to a collagen-coated 
scaffold, induced osteogenic differentiation of human mes-
enchymal stem cells when these cells were implanted into 
nude mice.15
In the present study, we extend our previous work and 
demonstrate that CBD-BMP4 is retained longer at the 
targeted sites compared to BMP4 alone and induced aug-
mented bone formation even when injected without scaffold. 
 Considering that the 100 kDa of fibronectin fragment that 
includes CBD (45 kDa) was reported to be about 24 nm,16 
CBD size can be regarded as a nanocarrier. When applied to 
cranial bone defects, CBD-BMP4 successfully induced new 
and accelerated bone formation as compared to BMP4 alone. 
Thus, CBD-BMP4 may be promising for the treatment of 
bone defects and nonunions.
Materials and methods
CBD-BMP4
CBD-BMP4 fusion protein was prepared as described.15 In 
brief, the recombinant protein was produced by transgenic 
silkworms, which carried a chimeric gene encoding CBD 
of human fibronectin and human BMP4 (mature form). The 
enterokinase recognition sequence was inserted between 
the CBD and BMP4 sequences. The fusion protein pro-
duced by and secreted into cocoons was extracted with 
CaCl
2
 and affinity-purified by Gelatin Sepharose 4B (GE 
Healthcare, Waukesha, WI, USA). CBD protein (without 
BMP4 fusion) was prepared as described.17 Control BMP4 
was purchased from R&D Systems, Inc (Minneapolis, 
MN, USA). For some experiments, CBD-BMP4, BMP4, 
and CBD were labeled with HiLyte Fluor 555 (Dojindo 
Molecular Technologies, Inc, Kumamoto, Japan), accord-
ing to the manufacturers’ instructions. In brief, NH
2
-
reactive HiLyte Fluor 555 dissolved in 10 µL dimethyl 
sulfoxide was mixed with CBD-BMP4, BMP4, or CBD 
solution (10 µg protein in 100 µL of phosphate buffered 
saline [PBS]). The protein-dye solution was incubated for 
10 minutes at 37°C and unreacted free dye was removed 
by centrifugation (8000 × g, 10 minutes) using a provided 
filtration tube. The labeled protein was then recovered from 
the filter membrane.
Characterization of CBD-BMP4
Purified protein was digested with enterokinase (EK Max, 
Life Technologies, Carlsbad, CA, USA), fractionated on 
sodium dodecyl sulfate-polyacrylamide gel, and transferred 
to a polyvinylidene difluoride membrane. The gel was 
stained with Coomassie Brilliant Blue. The membrane was 
incubated with anti-BMP4 goat serum (R&D Systems, Inc), 
followed by incubation with horseradish peroxidase-linked 
antigoat immunoglobulin G antibody (Vector Laboratories, 
Inc, Burlingame, CA, USA), and visualized using the ECL 
system (GE Healthcare). To assess binding stability, CBD-
BMP4 or BMP4 was mixed with 0.2% collagen solution 
in Eagle’s minimal essential medium, pH 7.4 (Koken Co, 
Tokyo, Japan), and the mixture (30 µL) was gelled at 37°C 
for 1 hour. PBS (150 µL) was then added and the overlaid 
PBS was collected after 1 hour, 3 hours, 1 day, 3 days, and 
7 days. Protein released into PBS solution was dot-blotted 
to a nitrocellulose membrane, followed by immunostaining 
with goat anti-BMP4 and the secondary antibody, as above. 
The reaction was visualized using 4-chloronaphthol as a 
horseradish peroxidase substrate.
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Animals
New Zealand White rabbits (female, 2.0 kg–2.5 kg) were 
purchased from Shimizu Laboratory Supplies (Kyoto, 
Japan). BALB/c mice (female, 6–8 weeks) were obtained 
from Charles River Laboratories (Yokohama, Japan). 
 Animals were housed in a temperature-controlled environ-
ment with a 12-hour light/12-hour dark cycle under specific 
pathogen-free conditions and allowed free access to water 
and food. The animal care and use committee at Okayama 
University approved all animal experiments conducted in 
this study.
Collagen–sponge scaffold model
Rabbits were anesthetized with an intramuscular injection of 
ketamine (80 mg/kg). Both knees were shaved and draped in a 
sterile fashion, and a medial incision was made. A bone hole 
was made in the distal diaphysis of the femur with a ϕ5.0 mm 
drill, and a collagen sponge (3 mm cylinder, atelocollagen 
sponge, MIGHTY; Koken Co, Tokyo, Japan) was intramed-
ullary implanted though the hole. The collagen sponge was 
presoaked with CBD-BMP4, BMP4, or CBD solution, and 
contained 1 µg of each protein. A sponge soaked with vehicle 
PBS alone was used as a control. These four groups of colla-
gen sponges were randomly implanted into rabbit femurs (ten 
rabbits, 20 femurs, five femurs per each group). Rabbits were 
then housed in each cage without knee immobilization until 
the time of evaluation. Rabbits were sacrificed 4 weeks later, 
and the collagen sponge was retrieved from the femur, fixed 
in 10% formalin, decalcified in 10% ethylenediaminetetra-
acetic acid (EDTA), embedded in paraffin, and the sections 
were stained with hematoxylin–eosin. Histological sections 
were digitalized under a microscope, and the ossification area 
in the sponge was measured by image-analyzing software, 
WinROOF (Mitani Corp, Fukui, Japan). The peripheral area 
of each sponge was deselected to exclude bone ingrowth by 
spontaneous healing. To assess the retainment of CBD-BMP4, 
BMP4, or CBD in vivo, a collagen sponge containing 1 µg of 
each protein fluorescently labeled was implanted as described 
above. Sponges soaked with vehicle PBS alone were used as 
controls (six rabbits, 12 femurs, three femurs per each group). 
On days 1, 3, and 14 after the implantation, rabbits were killed, 
and the sponge was removed, frozen in Super CryoEmbed-
ding Medium compound (Section-Lab Co, Hiroshima, Japan) 
and cut with a tungsten blade at −20°C, as described.18 The 
sections were stained with calcein acetomethoxy (40 µg/mL; 
Dojindo Molecular Technologies) for bony calcium detection 
and evaluated under a fluorescence microscope.
Intramedullary injection model
Mice were anesthetized with ketamine (100 mg/kg). Both 
knees were shaved, and the skin was cleaned with 70% 
ethanol. A bone hole was made in the distal diaphysis of the 
femur with a 24 G needle, and CBD-BMP4, BMP4, or CBD 
(100 ng in 10 µL PBS) was injected into the medullary cavity 
of the right femur with a 27 G needle-tipped syringe. The 
left femur injected with 10 µL PBS was used as a control 
(five mice per each group). At 4 weeks after the injection, 
the mice were sacrificed, and the femurs were resected. The 
femurs were scanned by microcomputed tomography (micro-
CT) (LaTheta LCT-200; Hitachi Aloka Medical, Ltd, Tokyo, 
Japan) using 48 µm slices (0.3 mm interval), and the bone 
mineral density (BMD) of individual trabecular bone area 
was calculated by accompanying image-analyzing software, 
LaTheta v1.20. In some mice, the bone marrow was washed 
with saline and the cells were stored at −80°C for messenger 
ribonucleic acid (mRNA) expression study. To assess the 
retainment of CBD-BMP4, BMP4, or CBD in vivo, each 
protein fluorescently labeled (1 µg in 10 µL PBS) or vehicle 
(10 µL PBS) was directly injected into the femur as described 
above (three mice per group). Mice were sacrificed on day 1, 
3, and 14 after the injection and nondecalcification femurs 
were cut with a tungsten blade at −20°C, and the sections 
were stained with calcein acetomethoxy and evaluated under 
a fluorescence microscope.
Bone defect model
Bone defects were made in the cranial bone, as previously 
described.19 Briefly, mice were anesthetized with ketamine 
(100 mg/kg), and the cranial bone was exposed. Bone 
defects were made in the parietal bone with a ϕ3.0 mm 
drill. After washing with saline, CBD-BMP4, BMP4, CBD 
(100 ng in 5 µL PBS), or vehicle (5 µL PBS), was applied 
to the defects, and the scalp was closed (five mice per each 
group). At 2 weeks after the surgery, the mice were killed, 
and the cranial bone was scanned by micro-CT in 48 µm 
slices. To analyze the ossification area, regions of interest 
were set on the bone defect area, and the accumulation of 
dots (counts per pixel) in the selected region of interest was 
measured using image-analyzing software (WinROOF; 
Mitani Corp). Three-dimensional images were reconstructed 
by the image-processing software, OsiriX (Pixmeo SARL, 
Bernex, Switzerland). Subsequently, the defect area was 
resected, fixed in 10% formalin, decalcified in 10% EDTA, 
embedded in paraffin, and the sections were stained with 
hematoxylin–eosin.
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Quantitative real-time PCR
Samples were homogenized in lysis buffer (QuickGene; 
Fujifilm, Tokyo, Japan), and total ribonucleic acid (RNA) 
was isolated, according to the manufacturer’s instructions. 
First-strand complementary deoxyribonucleic acid (cDNA) 
was constructed from 2 µg of total RNA with oligo (dT) 
as primers,12–18 and the cDNAs were used as a template for 
polymerase chain reaction (PCR). Quantitative real-time 
PCR was performed with SYBR PCR master mix (Agilent 
Technologies, Santa Clara, CA, USA) and specific primers. 
To validate the SYBR Green PCR products, a dissociation 
step was done to verify the T
m
 (annealing temperature) of 
the SYBR Green PCR product after the PCR were run. 
The expression levels of each mRNA were normalized 
by the expression of a housekeeping gene hypoxanthine 
 phosphoribosyltransferase. The primers used in this study 
are listed in Table 1.
Statistical analysis
Statistical analyses were performed using Student’s t-test 
for paired samples and analysis of variance for multiple 
samples. All data were expressed as the mean ± standard 
error of the mean. P , 0.05 was considered statistically 
significant.
Results
Characterization of CBD-BMP4
Recombinant CBD-BMP4 was purified from cocoons of 
transgenic silkworms. Calculated molecular sizes of CBD-
BMP4, CBD, and BMP4 moieties were 52.5 kDa, 39 kDa, 
and 13 kDa, respectively. As confirmed by enterokinase 
digestion, this fusion protein consisted of CBD and BMP4. 
BMP4 moiety released from CBD was immunoreactive with 
an anti-BMP4 antibody (Figure 1A). In in vitro experiments, 
CBD-BMP4 in a collagen gel was entrapped and localized for 
at least 7 days while unfused BMP4 diffused out of the gel as 
early as 1 hour and was undetectable after 1 day  (Figure 1B), 
indicating that CBD-BMP4 showed much higher collagen-
binding affinity than did BMP4.
Enhanced bone formation  
in collagen–sponge scaffold
We next asked whether CBD-BMP4 could display enhanced 
collagen-binding capacity in vivo and promote bone 
Table 1 Primers for quantitative real-time PCR
Gene Orientation Primer sequence (5′ to 3′)
ALP Forward 
Reverse
TGAGCGACACGGACAAGA 
GGCCTGGTAGTTGTTGTGAG
BSP Forward 
Reverse
TTCCCAGGTGTGTCATTGAAGA 
GGTATGTTTGCGCAGTTAGCAA
Osterix Forward 
Reverse
GGAGGTTTCACTCCATTCCA 
TAGAAGGAGCAAGGGGACAGA
Osteocalcin Forward 
Reverse
GCCATCACCCTGTCTCCTAA 
GCTGTGGAGAAGACACACGA
Runx2 Forward 
Reverse
GCCGGGAATGATGAGAACTA 
GGACCGTCCACTGTCACTTT
BMP2 Forward 
Reverse
ACGTCCTCAGCGAATTTGAG 
GCCTGCGGTACAGATCTAGC
BMP4 Forward 
 
Reverse
GCCGGAGGGCCAAGCGTAGCC 
CTAAG 
CTGCCTGATCTCAGCGGCACCC 
ACATC
TGFβ Forward 
Reverse
CAACAATTCCTGGCGTTACCTTGG 
GAAAGCCCTGTATTCCGTCTCCTT
HPRT Forward 
Reverse
TGACACTGGCAAAACAATGCA 
GGTCCTTTTCACCAGCAAGCT
Abbreviations: PCR, polymerase chain reaction; ALP, alkaline phosphatase; 
BSP, bone sialoprotein; Runx, runt-related transcription factor; BMP, bone 
morphogenetic protein; TGF, transforming growth factor; HPRT, hypoxanthine 
phosphoribosyltransferase.
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1 h input3 h 1 d 3 d 7 d
CBD-BMP4 
BMP4 
Incubation time
A
Gel
10
15
20
25
37
50
75
+ +
Enterokinase
M
CBD-BMP4 
CBD 
BMP4
kDa
Membrane
−−
Figure 1 Characterization of CBD-BMP4. (A) Purified CBD-BMP4 was digested 
with enterokinase, fractionated on SDS-polyacrylamide gel, and transferred to a 
PVDF membrane. The gel was stained with Coomassie Brilliant Blue (left), and the 
membrane was immunoblotted with anti-BMP4 (right). (B) BMP4 or CBD-BMP4 
was mixed with collagen solution, and the mixture was gelled at 37°C for 1 hour. 
Note: Protein released into PBS solution was blotted to a nitrocellulose membrane 
and immunodetected with anti-BMP4.
Abbreviations: CBD, collagen-binding domain; BMP4, bone morphogenetic 
protein-4; SDS, sodium dodecyl sulfate; PVDF, polyvinylidene difluoride; PBS, 
phosphate buffered saline.
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 formation more effectively than BMP4 alone. To examine 
this,  collagen sponges containing 1 µg of CBD-BMP4, BMP4, 
or CBD were placed in the rabbit femur, as described in the 
Methods section. The immunohistological data in  Figure 2 
demonstrated that BMP4 was found localized on day 1, but 
was no longer visible on day 3 after the  implantation. A scant 
calcification was seen on day 14 (Figure 2).
In the case of CBD-BMP4, a stronger signal was seen 
on day 1 relative to BMP4, and the signal intensity did not 
diminish by day 3. Results with CBD alone were similar to 
those of the fusion protein at day 3. Of note was the finding 
that only CBD-BMP4 appeared to induce robust calcifica-
tion in the site at day 14 (Figure 2). In another set of experi-
ments, histological examination 4 weeks later revealed that 
CBD-BMP4 induced a thicker trabecular bone formation 
than BMP4 did (Figure 3A). Further, the ossification area 
formed by CBD-BMP4 injected animals was significantly 
larger than seen in BMP4 injected animals (Figure 3B). CBD 
induced slightly augmented bone formation as compared to 
the PBS control. These data clearly showed that CBD-BMP4 
is retained longer at the given site in vivo, and induced bone 
formation more effectively than BMP4, CBD, or PBS when 
the fusion protein was implanted with scaffold.
Augmented bone formation  
without scaffold
Collagen is the major constituent of the bone matrix.20 The 
above data prompted us to investigate whether CBD-BMP4 
could remain at the given site without scaffold, leading to 
an augmented bone formation. To address this, we first 
confirmed the retainment of CBD-BMP4, BMP4, and CBD 
after a direct injection of fluorescence-labeled proteins 
(1 µg in 10 µL PBS) into the medullary cavity of mouse 
femur. The data in Figure 4 demonstrated that BMP4 was 
CBD-BMP4
BMP4
CBD
Day 1 Day 3 Day 14
250 µm 
PBS
Figure 2 Fluorescence images of a collagen sponge.
Notes: Collagen sponges containing fluorescence-labeled CBD-BMP4, BMP4, or CBD were implanted into rabbit femur. Sponges soaked with vehicle PBS were used as 
a control (three femurs per each group). On days 1, 3, and 14 after the implantation, the sponges were retrieved, and the sections were examined under a fluorescence 
microscope. HiLyte Fluor 555-labeled CBD-BMP4/BMP4/CBD is shown in red. Bone stained by calcein acetomethoxy is shown in green. Representative photographs from 
each group are shown.
Abbreviations: CBD, collagen-binding domain; BMP4, bone morphogenetic protein-4; PBS, phosphate buffered saline.
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Figure 3 CBD-BMP4 augments new bone formation when delivered by collagen sponges. Collagen sponges containing 1 µg of CBD-BMP4, BMP4, and CBD were implanted 
into rabbit femurs. Sponges soaked with vehicle PBS were used as a control (five femurs per each group). Four weeks later, the sponge was retrieved, fixed, decalcified, and 
the sections were stained with HE. (A) Histological sections of the collagen sponge. Representative photographs of each group are shown. : New bone (note osteocyte). 
: Collagen sponge. (B) Ossification area in the sponge was calculated (five femurs per each group).
Notes: §P , 0.05; †P , 0.01; P , 0.0001. Magnification is shown by the bar (100 µm).
Abbreviations: CBD, collagen-binding domain; BMP4, bone morphogenetic protein-4; PBS, phosphate buffered saline; HE, hematoxylin and eosin stain.
not found on day 3 after the injection, whereas CBD-BMP4 
was observed even after day 14. CBD remained in a similar 
fashion.  Apparent calcification was seen only next to CBD-
BMP4 on day 14 (Figure 4), suggesting enhanced new bone 
formation by CBD-BMP4.
We then assessed BMD by measuring micro-CT images 
(Figure 5A). BMD in mice treated with CBD-BMP4 at 4 
weeks later was increased compared to BMP4, CBD and 
PBS groups. There was no difference between the BMP4 
and PBS groups. BMD in CBD groups was higher than was 
seen in PBS groups (Figure 5B). The BMD in CBD-BMP4 
and BMP4 groups were also measured at 8 weeks after the 
injection and showed that BMD in CBD-BMP4 groups was 
higher than that observed in BMP4 groups (Figure 5C). 
BMD in the CBD-BMP4 groups at 8 weeks increased as 
compared to that at 4 weeks (737.1 ± 8.1 mg/cm3 versus 
703.5 ± 5.9 mg/cm3; respectively, P , 0.05, five mice each). 
No change was found in BMP4 groups (Figure 5C), suggest-
ing prolonged osteogenic activity with CBD-BMP4. These 
data indicate that a single injection of CBD-BMP4 augments 
bone formation even without scaffold.
Osteogenic gene expressions  
by CBD-BMP4
To better understand the molecular mechanisms underlying 
the augmented osteogenesis by intramedullary CBD-BMP4 
treatment, bone marrow cells were harvested from the femurs 
at 4 weeks after therapy injection and mRNA expression of 
osteogenic factors were examined. Osteoblast-associated fac-
tors including alkaline phosphatase (ALP), bone sialoprotein 
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500 µm
CBD-BMP4
BMP4
CBD
Day 1 Day 3 Day 14
PBS
Figure 4 Fluorescence images of mouse femur.
Notes: Fluorescence-labeled CBD-BMP4, BMP4 or CBD (1 µg in 10 µL PBS) were injected into mouse femurs. PBS alone (10 µL) was used as a control (three mice per each 
group). On day 1, 3, and 14 after the injection, the femurs were resected, frozen, cut, and examined under a fluorescence microscope. HiLyte Fluor 555-labeled CBD-BMP4/
BMP4/CBD is shown in red. Bone stained by calcein acetomethoxy is shown in green. Bone hole is shown in a dashed line. Shown were representative photographs from 
each group. Magnification is shown by the bar (500 µm).
Abbreviations: CBD, collagen-binding domain; BMP4, bone morphogenetic protein-4; PBS, phosphate buffered saline.
(BSP), osteocalcin, osterix, and Runt-related transcription 
factor 2 (Runx2) were expressed at higher levels in the 
CBD-BMP4 group than in the other groups, including the 
BMP4 group (Figure 6A).
In contrast, there was no difference between the 
BMP4 group and the PBS control. Interestingly, the CBD 
group showed increased ALP, BSP, and osteocalcin expres-
sion relative to the control PBS (Figure 6A). Endogenous 
expression of growth factors was examined next, which 
demonstrated that the CBD-BMP4 group, but not the 
BMP4 group, upregulated the expression of BMP2 and 
BMP4, as compared to PBS control. Augmented  expression 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1355
In vivo osteogenesis by CBD-BMP4
International Journal of Nanomedicine 2013:8
5.0 mm
CBD-BMP4 CBDBMP4 PBS
700
600
700
600
CBD-BMP4 BMP4
B
o
n
e 
m
in
er
al
 d
en
si
ty
mg/cm3 mg/cm3
A
B C
PBS
CBD-BMP4
CBD
BMP4
Figure 5 CBD-BMP4 accelerates bone mineral density. CBD-BMP4, BMP4, CBD (100 ng in 10 µL PBS), or vehicle PBS (10 µL) were directly injected into mouse femurs 
(five mice per each group). At 4 weeks after the injection, the femurs were scanned by micro-CT. (A) Representative images from each group. Bone mineral density was 
calculated by micro-CT at (B) 4 weeks and (C) 8 weeks after the injection. 
Notes: §P , 0.05; †P , 0.01.
Abbreviations: CBD, collagen-binding domain; BMP4, bone morphogenetic protein-4; PBS, phosphate buffered saline; CT, computed tomography.
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Figure 6 CBD-BMP4 increases osteogenic gene expression. Bone marrow cells were harvested at 4 weeks after the injection of CBD-BMP4, BMP4, CBD (100 ng in 10 µL 
PBS), or vehicle PBS (10 µL) (five mice per each group). mRNA expression for (A) osteoblast-associated factors and (B) bone growth factors were quantitated by RT-PCR. 
The expression levels of mRNA were normalized to HPRT. 
Notes: §P , 0.05; †P , 0.01.
Abbreviations: CBD, collagen-binding domain; BMP4, bone morphogenetic protein-4; ALP, alkaline phosphatase; BSP, bone sialoprotein; PBS, phosphate buffered saline; 
RT-PCR, reverse transcription polymerase chain reaction; HPRT, hypoxanthine phosphoribosyltransferase.
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of BMP4 was also found in the CBD group. No change 
was found in the expression level of TGFβ (Figure 6B). 
Thus, enhanced bone formation in the CBD-BMP4 group 
was associated with augmented expressions of osteogenic 
factors and growth factors. The BMP4 alone group failed 
to augment these factors during this time period (4 weeks 
after the injection), possibly due to the diffusion from the 
site (Figure 4). CBD, which was also present at the targeted 
site over a longer period, might stimulate bone formation by 
inducing endogenous BMP4.
Accelerated bone formation in a cranial 
bone defect model
To further strengthen the in vivo osteogenesis induced by 
CBD-BMP4, we applied CBD-BMP4, BMP4, CBD, or vehi-
cle in a cranial bone defect model without scaffold. BMP4 
treatment demonstrated new bone formation on day 14 after 
the treatment (Figure 7A). Obviously, CBD-BMP4 showed 
substantial ingrowth of new bone formation. As shown in 
Figure 7B, the ossification area induced by CBD-BMP4 
and BMP4 was statistically increased as compared to that 
by PBS control. Importantly, there was more new bone 
formation in the CBD-BMP4-treated group than that in the 
BMP4 group. Ossification area by CBD was similar to that 
of the PBS control (Figure 7B). Histological examination 
consistently demonstrated new bone formation lined by a 
layer of osteoblasts in the CBD-BMP4- and the BMP4-treated 
group, which was more prominent in the CBD-BMP4 group 
(Figure 7C).
Discussion
Immobilized growth factors targeting the extracellular matrix 
(ECM) can be more effective than diffusible, free growth 
factors.21 The goal of engineering a fusion protein was to 
deliver a functional substance that had limited diffusion over 
a prolonged period of time. Our novel BMP4 fusion protein 
with a nanosized carrier – namely, the CBD – seems to fulfill 
this requirement.15 The stable binding of CBD to collagen 
led us to investigate whether this novel CBD-BMP4 by itself 
could enhance bone formation using bone matrix collagen 
as an innate scaffold.
As expected, CBD-BMP4 induced stronger bone forma-
tion than did BMP4. CBD-BMP4 remained at the injected 
site for at least 2 weeks, possibly through the CBD binding 
to bone matrix collagen, and the results demonstrated that 
new bone formation continues to be observed even after 
8 weeks. There exist several kinds of gene-engineered 
binding growth factors, including BMPs.21 Our CBD-BMP4 
has advantages over other engineered fusion proteins. First, 
CBD-BMP4 induced entopic bone formation without using 
scaffold. As far as we know, this is the first report demon-
strating accelerated bone formation by a fusion protein on 
its own. Previous studies reported that collagen-binding 
BMP2 demonstrated ectopic bone formation when applied 
with bone-derived matrix as a scaffold.22,23 Bone-derived 
matrix contains many factors, including native BMPs, and 
the complex is not fully defined, suggesting potential dif-
ficulties in clinical use. Second, CBD-BMP4 was effective 
even in a single low dose. In the present study, we injected 
100 ng of CBD-BMP4 (≈2 pM), as preliminary experiments 
showed that BMP4 at this dose failed to induce appreciable 
bone formation at 4 weeks after the injection (not shown). 
Others used 8 nM CBD-BMP2 for ectopic bone formation 
model and 0.5 nM for the bone defect model.24 Although 
verification of whether higher amounts of CBD-BMP4 could 
induce stronger bone formation in a critical-sized bone 
defect remains to be completed, we believe that our results 
predict that CBD-BMP4 will be very efficient with larger 
doses. In a bone-defect model, 2.5 µg to 5 µg of recombinant 
BMP4 was applied with collagen sponge or beta-tricalcium 
phosphate.11 We believe our initial results also predict that, 
compared to other reagents, the CBD-BMP4 fusion pro-
tein will efficaciously require reduced amounts of protein 
to induce bone formation and thus limit possible clinical 
complications.
It appears that CBD-BMP4 both directly and indi-
rectly induced bone formation. We have demonstrated 
that CBD-BMP4 induced osteogenic differentiation using 
three- dimensional cultures of human bone marrow-derived 
mesenchymal stem cells.15 As shown in this study, CBD-
BMP4 treatment upregulated the expression of all relevant 
osteogenic genes examined in the target site, even after 
4 weeks postinjection, possibly due to the continued func-
tional localization of the fusion protein. ALP is a major 
biomarker of bone formation and plays a key role in bone 
mineralization.25 BSP is upregulated as osteoblasts mature 
at sites of de novo bone formation.26 Osteocalcin is an ECM 
protein and among the most specific markers for osteoblast 
maturation.27 Osterix is a bone-related transcription factor 
that functions genetically downstream of Runx2, which 
regulates the differentiation and/or function of osteoblasts.28,29 
In addition, CBD-BMP4 increased the expression of endog-
enous BMP2 and BMP4. Thus, CBD-BMP4 stimulated de 
novo expressions of osteogenic genes and bone growth fac-
tors for a longer period and initiated the calcification of the 
ECM, leading to the prolonged bone formation.
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Figure 7 CBD-BMP4 enhances bone formation in a cranial bone defect model. CBD-BMP4, BMP4, CBD (100 ng in 5 µL PBS), or vehicle PBS (5 µL) was applied to 
the defective section of cranial bone (five mice per each group). At 2 weeks after the injection, the mice were killed, and the bone defects were scanned by micro-CT. 
(A) Representative three-dimensional CT images from each group. (B) Ossification area was calculated by micro-CT. §P , 0.05; †P , 0.01. (C) Representative tissue sections 
from each group are shown (HE staining).
Note: Arrowheads indicated the layer of osteoblasts.
Abbreviations: CBD, collagen-binding domain; BMP4, bone morphogenetic protein-4; PBS, phosphate buffered saline; CT, computed tomography; HE, hematoxylin and 
eosin stain.
Of note was the finding that CBD by itself somewhat 
induced bone formation when intramedullary injected. 
 Similar to CBD-BMP4, CBD remained at the injected site. 
The CBD used in this fusion protein was from fibronectin,17 
which is an ECM component. ECMs and growth factors 
function cooperatively to stimulate osteoblast differentiation. 
There is evidence to suggest a role for fibronectin in the early 
stages of bone formation.30,31 Recently, it has been demon-
strated that ECMs including fibronectin modified the growth 
patterns and induced the osteoblast differentiation of human 
myeloid stem cells, as evidenced by increased expressions 
of ALP, osteocalcin, osterix, and Runx2.32 Accordingly, we 
showed in this study that CBD upregulated the expressions 
of osteogenic genes such as ALP, BSP, and osteocalcin, and 
growth factor BMP4. Although CBD is a segment (amino 
acids 260–599) of the original fibronectin,15 CBD may con-
tain fibronectin’s active site leading to osteogenesis. Thus, the 
osteogenic capacity of CBD-BMP4 may be partly due to the 
activity of CBD. A question arises as to whether the simulta-
neous injection of CBD and BMP4 could represent additive 
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or synergistic osteogenic effects, which was not examined 
in this study. CBD-BMP4 had no osteogenic effects when 
applied to the defective section of cranial bone. The disparity 
may be due to the different location of the given site (bone 
marrow versus cortical bone).
There are several other concerns that were not confronted 
in this study. Although we believe that CBD-BMP4 binds to 
bone matrix collagen at the injection site, we have not shown 
direct evidence. It is not clear how CBD-BMP4 interacts 
with the BMP4 receptor at the site and how CBD-BMP4 
itself affects the surrounding cells, either when acting as a 
complex or as individual components. CBD-BMP4 has a 
higher molecular weight than BMP4, which may contribute 
to the physics of diffusion. Further studies are necessary to 
explore these precise mechanisms.
Conclusion
In conclusion, our engineered CBD-BMP4 is a novel fusion 
protein with an exquisite ability to promote in vivo osteogen-
esis, even by a single injection at the targeted site both with 
and without scaffold. There are many ways to enhance the 
release of BMP4 using chemical conjugation, particle vehicle, 
or gene delivery, which are low cost, verified, and convenient. 
We believe that our fusion protein is better than others, as 
CBD-BMP4 can localize longer at the designated site, resulting 
in stronger bone formation by a single low dose of complex. 
This novel CBD-BMP4 may be promising clinically for the 
treatment of unresolved fractures, bone defects, and other bone 
tissue engineering and regeneration-related scenarios.
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